AIM: To investigate the effect of resveratrol on biliary secretion of cholephilic compounds in healthy and bile duct-obstructed rats. METHODS: Resveratrol (RSV) or saline were administered to rats by daily oral gavage for 28 d after sham operation or reversible bile duct obstruction (BDO). Bile was collected 24 h after the last gavage during an intravenous bolus dose of the Mdr1/Mrp2 substrate azithromycin. Bile acids, glutathione and azithromycin were measured in bile to quantify their level of biliary secretion. Liver expression of enzymes and transporters relevant for bile production and biliary secretion of major bile constituents and drugs were analyzed at the mRNA and protein levels using qRT-PCR and Western blot analysis, respectively. The TR-FRET PXR Competitive Binding Assay kit was used to determine the agonism of RSV at the pregnane X receptor. RESULTS: RSV increased bile flow in sham-operated rats due to increased biliary secretion of bile acids (BA) and glutathione. This effect was accompanied by the induction of the hepatic rate-limiting transporters for bile acids and glutathione, Bsep and Mrp2, respectively. RSV also induced Cyp7a1, an enzyme that is crucial for bile acid synthesis; Mrp4, a transporter important for BA secretion from hepatocytes to blood; and Mdr1, the major apical transporter for xenobiotics. The findings were supported by increased biliary secretion of azithromycin. The TR-FRET PXR competitive binding assay confirmed RSV as a weak agonist of the human nuclear receptor PXR, which is a transcriptional regulator of Mdr1/Mrp2. RSV demonstrated significant hepatoprotective properties against BDO-induced cirrhosis. RSV also reduced bile flow in BDO rats without any corresponding change in the levels of the transporters and enzymes involved in RSV-mediated hepatoprotection. CONCLUSION: Resveratrol administration for 28 d has a distinct effect on bile flow and biliary secretion of cholephilic compounds in healthy and bile duct-obstructed rats.

Department of Biological and Medical Sciences Charles University Faculty of Pharmacy in Hradec Kralove 50003 Hradec Kralove Czech Republic

Department of Histology and Embryology Charles University Faculty of Medicine in Hradec Kralove 50003 Hradec Kralove Czech Republic

Department of Medical Biochemistry Charles University Faculty of Medicine in Hradec Kralove 50003 Hradec Kralove Czech Republic

Department of Pharmacology and Toxicology Charles University Faculty of Pharmacy in Hradec Kralove 50003 Hradec Kralove Czech Republic

Department of Pharmacology Charles University Faculty of Medicine in Hradec Kralove 50003 Hradec Kralove Czech Republic

Department of Physiology Charles University Faculty of Medicine in Hradec Kralove 50003 Hradec Kralove Czech Republic

Zobrazit více v PubMed

Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3:1035–1078. PubMed PMC

Brandoni A, Hazelhoff MH, Bulacio RP, Torres AM. Expression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis. World J Gastroenterol. 2012;18:6387–6397. PubMed PMC

Roma MG, Crocenzi FA, Mottino AD. Dynamic localization of hepatocellular transporters in health and disease. World J Gastroenterol. 2008;14:6786–6801. PubMed PMC

Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta. 2007;1773:283–308. PubMed

Amiot MJ, Riva C, Vinet A. Effects of dietary polyphenols on metabolic syndrome features in humans: a systematic review. Obes Rev. 2016;17:573–586. PubMed

Bunaciu RP, Yen A. Resveratrol and Malignancies. Curr Pharmacol Rep. 2015;1:266–271. PubMed PMC

Udenigwe CC, Ramprasath VR, Aluko RE, Jones PJ. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008;66:445–454. PubMed

Heebøll S, Thomsen KL, Pedersen SB, Vilstrup H, George J, Grønbæk H. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World J Hepatol. 2014;6:188–198. PubMed PMC

Ferramosca A, Di Giacomo M, Zara V. Antioxidant dietary approach in treatment of fatty liver: New insights and updates. World J Gastroenterol. 2017;23:4146–4157. PubMed PMC

Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol. 2008;28:93–103. PubMed

Wang Y, Jiang Y, Fan X, Tan H, Zeng H, Wang Y, Chen P, Huang M, Bi H. Hepato-protective effect of resveratrol against acetaminophen-induced liver injury is associated with inhibition of CYP-mediated bioactivation and regulation of SIRT1-p53 signaling pathways. Toxicol Lett. 2015;236:82–89. PubMed

Ara C, Kirimlioglu H, Karabulut AB, Coban S, Ay S, Harputluoglu M, Kirimlioglu V, Yilmaz S. Protective effect of resveratrol against oxidative stress in cholestasis. J Surg Res. 2005;127:112–117. PubMed

Kirimlioglu V, Ara C, Yilmaz M, Ozgor D, Isik B, Sogutlu G, Kirimlioglu H, Karabulut AB, Yilmaz S, Kayaalp C, et al. Resveratrol, a red wine constituent polyphenol, protects gastric tissue against the oxidative stress in cholestatic rats. Dig Dis Sci. 2006;51:298–302. PubMed

Tian Y, Ma J, Wang W, Zhang L, Xu J, Wang K, Li D. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem. 2016;422:75–84. PubMed

Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L, Chen SH, Zhang T, Zhou X, Zou D, et al. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res. 2015;59:1443–1457. PubMed

Wang T, Zhou ZX, Sun LX, Li X, Xu ZM, Chen M, Zhao GL, Jiang ZZ, Zhang LY. Resveratrol effectively attenuates alpha-naphthylisothiocyanate-induced acute cholestasis and liver injury through choleretic and anti-inflammatory mechanisms. Acta Pharmacologica Sinica. 2014;35:1527–1536. PubMed PMC

Cenesiz S, Yarim GF, Karabulut AB, Ara C. Changing of antioxidant enzyme activity on the biliary obstructed rats treated with resveratrol. Dtsch Tierarztl Wochenschr. 2007;114:345–348. PubMed

Hirsova P, Karlasova G, Dolezelova E, Cermanova J, Zagorova M, Kadova Z, Hroch M, Sispera L, Tomsik P, Lenicek M, et al. Cholestatic effect of epigallocatechin gallate in rats is mediated via decreased expression of Mrp2. Toxicology. 2013;303:9–15. PubMed

Fuksa L, Brcakova E, Cermanova J, Hroch M, Chladek J, Kolouchova G, Malakova J, Martinkova J, Staud F, Micuda S. Amiodarone modulates pharmacokinetics of low-dose methotrexate in rats. Biopharm Drug Dispos. 2008;29:289–299. PubMed

Maly IP, Landmann L. Bile duct ligation in the rat causes upregulation of ZO-2 and decreased colocalization of claudins with ZO-1 and occludin. Histochem Cell Biol. 2008;129:289–299. PubMed

Kolouchova G, Brcakova E, Hirsova P, Sispera L, Tomsik P, Cermanova J, Hyspler R, Slanarova M, Fuksa L, Lotkova H, et al. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. J Gastroenterol Hepatol. 2011;26:1544–1551. PubMed

Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol. 2009;51:565–580. PubMed

Brcakova E, Fuksa L, Cermanova J, Kolouchova G, Hroch M, Hirsova P, Martinkova J, Staud F, Micuda S. Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats. Biol Pharm Bull. 2009;32:1978–1985. PubMed

Chen ML, Yi L, Zhang Y, Zhou X, Ran L, Yang J, Zhu JD, Zhang QY, Mi MT. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota. MBio. 2016;7:e02210–e02215. PubMed PMC

Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003;73:1393–1400. PubMed

Shao D, Wang Y, Huang Q, Shi J, Yang H, Pan Z, Jin M, Zhao H, Xu X. Cholesterol-Lowering Effects and Mechanisms in View of Bile Acid Pathway of Resveratrol and Resveratrol Glucuronides. J Food Sci. 2016 Epub ahead of print. PubMed

Halilbasic E, Baghdasaryan A, Trauner M. Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis. 2013;17:161–189. PubMed PMC

Shoda J, Miura T, Utsunomiya H, Oda K, Yamamoto M, Kano M, Ikegami T, Tanaka N, Akita H, Ito K, et al. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver. Hepatology. 2004;39:167–178. PubMed

Misra S, Varticovski L, Arias IM. Mechanisms by which cAMP increases bile acid secretion in rat liver and canalicular membrane vesicles. Am J Physiol Gastrointest Liver Physiol. 2003;285:G316–G324. PubMed

Fukami M, Tanka A, Takikawa H. Effect of penicillin G on the biliary excretion of cholephilic compounds in rats. J Hepatobiliary Pancreat Sci. 2011;18:684–688. PubMed

Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med. 2014;37:57–76. PubMed PMC

Cermanova J, Kadova Z, Zagorova M, Hroch M, Tomsik P, Nachtigal P, Kudlackova Z, Pavek P, Dubecka M, Ceckova M, et al. Boldine enhances bile production in rats via osmotic and farnesoid X receptor dependent mechanisms. Toxicol Appl Pharmacol. 2015;285:12–22. PubMed

Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther. 2002;302:369–373. PubMed

Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, Kitaichi K, Takagi K, Takagi K, Hasegawa T. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004;48:809–814. PubMed PMC

Yang S-Y, Tsai S-Y, Hou Y-C, Chao P-DL. Inductive modulation on P-glycoprotein and cytochrome 3A by resveratrol, a constituent of grapes. Food Chem. 2012;133:683–688.

Smutny T, Pavek P. Resveratrol as an inhibitor of pregnane X receptor (PXR): another lesson in PXR antagonism. J Pharmacol Sci. 2014;126:177–178. PubMed

Vitrac X, Desmoulière A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J, Mérillon JM. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003;72:2219–2233. PubMed

Detampel P, Beck M, Krähenbühl S, Huwyler J. Drug interaction potential of resveratrol. Drug Metab Rev. 2012;44:253–265. PubMed

Jia Y, Liu Z, Wang C, Meng Q, Huo X, Liu Q, Sun H, Sun P, Yang X, Ma X, et al. P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016;306:27–35. PubMed

Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Weiglein AH, Lammert F, Marschall HU, Tsybrovskyy O, Zatloukal K, Denk H, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology. 2002;123:1238–1251. PubMed

Chan CC, Cheng LY, Lin CL, Huang YH, Lin HC, Lee FY. The protective role of natural phytoalexin resveratrol on inflammation, fibrosis and regeneration in cholestatic liver injury. Mol Nutr Food Res. 2011;55:1841–1849. PubMed

Trauner M, Boyer JL. Cholestatic syndromes. Curr Opin Gastroenterol. 2004;20:220–230. PubMed

Zelenka J, Muchova L, Zelenkova M, Vanova K, Vreman HJ, Wong RJ, Vitek L. Intracellular accumulation of bilirubin as a defense mechanism against increased oxidative stress. Biochimie. 2012;94:1821–1827. PubMed

Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol. 2011;178:175–186. PubMed PMC

Micuda S, Brcakova E, Fuksa L, Cermanova J, Osterreicher J, Hroch M, Mokry J, Pejchal J, Martinkova J, Staud F. P-glycoprotein function and expression during obstructive cholestasis in rats. Eur J Gastroenterol Hepatol. 2008;20:404–412. PubMed